NVAX

https://finance.yahoo.com/news/novavaxs-nvax-covid-jab-gets-160200977.html

Novavax NVAX announced that the European Commission had granted full marketing authorization for its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU). The vaccine is approved as a primary series for individuals aged 12 and older and as a booster for those aged 18 and above.

The European Medicines Agency's Committee for Medicinal Products for Human Use had previously provided a positive opinion on the vaccine, paving the way for its full authorization.

Nuvaxovid initially obtained conditional marketing approval in the EU as a booster dose for adults aged 18 years and above in September 2022. Presently, the vaccine is approved for use in more than 40 global markets.